Race Oncology (ASX: $RAC) presents promising results for AML treatment

Race Oncology Limited (ASX: $RAC) presented promising pre-clinical results at the New Directions in Leukaemia Research conference in Adelaide. The results demonstrate the potent anticancer activity of bisantrene, both as a single drug and in combination with decitabine, for the treatment of acute myeloid leukemia (AML).

Executive Commentary on Bisantrene and Decitabine Combination

The preclinical evaluation of bisantrene alone and in combination with decitabine for AML has shown highly promising results. The combination of bisantrene and decitabine exhibits robust anticancer synergy in both cell and mouse AML models, indicating a potential low-intensity treatment approach for AML patients. The identification of key cellular pathways targeted by bisantrene further supports its potential in combination with decitabine for AML therapy. These results are expected to pave the way for clinical trials of Race's new bisantrene formulation (RC220) combined with oral decitabine, offering hope for improved treatment options for AML patients.

Summary of Bisantrene and Decitabine Preclinical Evaluation

The preclinical evaluation of bisantrene alone and in combination with decitabine has demonstrated potent anticancer activity in diverse cell and animal models of Acute Myeloid Leukemia (AML). The combination of bisantrene and decitabine exhibits robust anticancer synergy, with significantly higher anticancer activity when used together. The identification of key cellular pathways targeted by the combination further supports the potential of bisantrene in combination with decitabine as a low-intensity treatment for AML patients. These promising results are expected to lead to clinical trials of Race's new bisantrene formulation (RC220) combined with oral decitabine, offering hope for improved treatment options for AML patients.